Cart
sales@molnova.com
WAY127093B racemate
CAS No. 145743-63-1
WAY127093B racemate( —— )
Catalog No. M33170 CAS No. 145743-63-1
WAY127093B racemate is the racemic mixture of WAY127093B, a phosphodiesterase IV inhibitor with demonstrated oral activity in rats and guinea pigs.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 119 | In Stock |
|
| 5MG | 107 | In Stock |
|
| 10MG | 158 | In Stock |
|
| 25MG | 236 | In Stock |
|
| 50MG | 326 | In Stock |
|
| 100MG | 437 | In Stock |
|
| 200MG | 579 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameWAY127093B racemate
-
NoteResearch use only, not for human use.
-
Brief DescriptionWAY127093B racemate is the racemic mixture of WAY127093B, a phosphodiesterase IV inhibitor with demonstrated oral activity in rats and guinea pigs.
-
DescriptionWAY127093B racemate is the racemate of WAY127093B. WAY127093B is an orally active phosphodiesterase IV inhibitor in guinea pigs and rats.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetPDE
-
RecptorPDE
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number145743-63-1
-
Formula Weight424.49
-
Molecular FormulaC23H28N4O4
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCN1C(CC(=O)N1C(NCC=2C=CC=NC2)=O)C3=CC(OC4CCCC4)=C(OC)C=C3
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Howell RE, et al. Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats. Inflamm Res. 1995 Aug;44 Suppl 2:S172-3.?
molnova catalog
related products
-
Avanafil
A potent and highly selective PDE5 inhibitor (IC50=5.2 nM) for erectile dysfunction.
-
Ensifentrine
Ensifentrine is a PDE3/4 inhibitor, although its affinity for PDE3(IC50: 0.4 nM) is 3,440 times higher than that for PDE4(IC50: 1479 nM), that is under clinical development for the treatment of asthma and COPD and, potentially, cystic fibrosis.
-
BRL 50481
BRL-50481 is a novel and selective inhibitor of PDE7 with IC50s of 0.15 12.1 62 and 490 μM for PDE7A PDE7B PDE4 and PDE3 respectively.
